Results 171 to 180 of about 1,744,557 (311)

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Nitrofurantoin as a preferred first-line therapy for urinary tract infection: A comparison using urinary tract infection-specific antibiograms. [PDF]

Bladder (San Franc)
Souders CP, Clark A, Prokesch BC, Zimmern PE.   +3 more
europepmc   +1 more source

Molecular basis of Escherichia coli colonization of the upper urinary tract in BALB/c mice. Gal-Gal pili immunization prevents Escherichia coli pyelonephritis in the BALB/c mouse model of human pyelonephritis. [PDF]

, 1985
P O’Hanley, D Lark, Stanley Falkow, Gary K. Schoolnik   +3 more
openalex   +1 more source

Efficacy and safety of empagliflozin for treating neutropenia and neutrophil dysfunction in paediatric patients with glycogen storage disease type Ib: A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims Glycogen storage disease type Ib (GSD‐Ib) is a rare genetic disorder causing neutropenia and neutrophil dysfunction in children. G‐CSF has been the primary treatment, but emerging data support the potential of empagliflozin, an SGLT2 inhibitor, as a promising investigational option.
Elizabeth Iwasyk, Ryan Jin, Fabio Tuzzolino, Giusy Ranucci, Donatella Madonia, Alessio Provenzani   +5 more
wiley   +1 more source

A pilot intervention to improve the management of urinary tract infections in outpatient settings. [PDF]

Antimicrob Steward Healthc Epidemiol
Madaras-Kelly KJ, Nakasone T, Maghari S, Taylor J, Nevers M, Crook J, Brintz B, Braunfeld JB, Goetz MB, Samore M.   +9 more
europepmc   +1 more source

Pivmecillinam in the treatment of urinary tract infections [PDF]

, 2000
Lindsay E. Nicolle
openalex   +1 more source

Prescription use of acetaminophen among pregnant women in Denmark from 2000 to 2023: A drug utilization study

British Journal of Clinical Pharmacology, EarlyView.
Aims The aim of this study was to describe prescription use of acetaminophen, a widely used analgesic and antipyretic generally considered safe during pregnancy, among pregnant women from 2000 to 2023 in Denmark with special attention towards variations following the change in over‐the‐counter (OTC) availability in 2013.
Erika B. Gram, Mette Bliddal, Sophie Pflugfelder, Peter Bjødstrup Jensen, Per Damkier   +4 more
wiley   +1 more source

Epidemiology of fungal urinary tract infections: A retrospective case series. [PDF]

New Microbes New Infect
Khateb AM, Alamri LS, Alseyoufi WA, Almusaiferi YH, Safdar OY.   +4 more
europepmc   +1 more source

Nonantibiotic prevention and management of recurrent urinary tract infection

Nature reviews. Urology, 2018
N. Sihra, A. Goodman, R. Zakri, A. Sahai, S. Malde   +4 more
semanticscholar   +1 more source

Pharmacokinetics of teicoplanin in paediatric patients—A systematic review of current literature

British Journal of Clinical Pharmacology, EarlyView.
Background and Objective Teicoplanin is commonly used in children to treat gram‐positive infections and is sometimes used off‐label prophylactically in surgical or paediatric oncology settings. The pharmacokinetics (PK) of teicoplanin in children exhibit considerable variability, such as in critically ill children or those with renal impairment.
Noa E. Wijnen, Daan J. Touw, Kim Klein, Gertjan J. L. Kaspers, Paola Mian   +4 more
wiley   +1 more source